Finance

Beta
Lists
MLYS:NASDAQ
Mineralys Therapeutics Inc
$29.12
+5.16%
(+1.43) 1D
$29.12
0.00% (0.00)
After hours
Closed: Jul 6, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MLYS...
Open
$27.55
High
$29.97
Low
$27.01
Mkt. cap
2.57B
Avg. vol.
2.08M
Volume
1.72M
52-wk high
$47.65
52-wk low
$12.59
EPS
-$2.06
Beta
0.66
Shares outstanding
88.16M
No. of employees
76
Open
$27.55
High
$29.97
Low
$27.01
Mkt. cap
2.57B
Avg. vol.
2.08M
Volume
1.72M
52-wk high
$47.65
52-wk low
$12.59
EPS
-$2.06
Beta
0.66
Shares outstanding
88.16M
No. of employees
76
News stories
From sources across the web
About Mineralys Therapeutics Inc
CEO-
Employees76
Founded2019
Headquarters-
SectorBiotechnology
Websitemineralystx.com
Analyst ratings
Based on 7 analysts giving stock ratings to MLYS in the past 3 months
Strong buy
Buy
7
Hold
0
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for MLYS in the last 3 months.
Highest
Current $29.12
$56.00 (+92.31%)
Average
$50.40 (+73.08%)
Lowest
$42.00 (+44.23%)
Analyst
Recommendation
Action
Price target
Projected
Date
Richard Law CFA
Goldman Sachs
Buy
Maintained
$42.00
+44.2%
06/03/2026
Rami Katkhuda
LifeSci Capital
Buy
Reiterated
$54.00
+85.4%
06/01/2026
Matthew Caufield
H.C. Wainwright
Buy
Reiterated
$56.00
+92.3%
06/01/2026
Seamus Fernandez
Guggenheim
Buy
Maintained
$48.00
+64.8%
05/18/2026
Jason Gerberry
Bank of America Securities
Buy
Maintained
-
-
05/07/2026
Annabel Samimy
Stifel Nicolaus
Buy
Maintained
$52.00
+78.6%
05/07/2026
Unknown Analyst
Goldman Sachs
Buy
Reiterated
$42.00
+44.2%
05/07/2026
Tara Bancroft
TD Cowen
Buy
Maintained
-
-
05/06/2026
Mohit Bansal
Wells Fargo
Buy
Maintained
$55.00
+88.9%
03/13/2026
Last report
May 6, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
-$0.47 / -$0.44
-6.82%miss
Revenue / Est. (USD)
- / 0.00
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
38.28M
31.45M
24.40M
24.36M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8.47M
9.68M
13.88M
20.98M
Operating expense
46.75M
41.13M
38.28M
45.34M
Total operating expenses
46.75M
41.13M
38.28M
45.34M
Operating income
-46.75M
-41.13M
-38.28M
-45.34M
Other non operating income
-2.00K
4.00K
1.00K
5.00K
EBT including unusual items
-43.27M
-36.93M
-32.23M
-39.34M
EBT excluding unusual items
-43.27M
-36.93M
-32.23M
-39.34M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-43.27M
-36.93M
-32.23M
-39.34M
Net profit margin
-
-
-
-
Earnings per share
-0.66
-0.52
-0.40
-0.47
Interest and investment income
3.47M
4.20M
6.04M
6.00M
Interest expense
-
-
-
-
Net interest expenses
3.47M
4.20M
6.04M
6.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
-46.73M
-41.12M
-38.27M
-45.33M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer